Stifel Maintains Buy on Beta Bionics, Lowers Price Target to $20
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $22 to $20.
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $22 to $20.